⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 22, 2025Future Oncology

The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis

Zeyi Zhao Lei Cheng Xin Tong Shuai Xu Qingqing Zhuang

View Full Paper

Ask AI

Bookmark

Share

Key Points

Adding bevacizumab improves treatment outcomes in advanced ovarian cancer, yet increases toxicity.
The analysis reveals significant efficacy metrics with the addition of bevacizumab, leading to higher response rates.
This study utilized a meta-analysis to combine data from multiple trials assessing bevacizumab in neoadjuvant settings.
The findings highlight the need for careful consideration of benefit versus risk when using bevacizumab in treatment plans.

Implication

Meta-analysis assesses efficacy and toxicity of bevacizumab with neoadjuvant chemotherapy for advanced ovarian cancer, suggesting complex benefits.

Abstract

Objective To appraise the efficacy and toxicity of adding bevacizumab to neoadjuvant chemotherapy (NACT) for advanced-stage ovarian cancer (AOC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/68c1ce7054b1d3bfb60f5949 https://doi.org/10.1080/14796694.2025.2548188

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma.Meta-Analysis · 2026
2Bevacizumab with Paclitaxel and Carboplatin as Neo Adjuvant Chemotherapy for Stage 4 Ovarian Cancer- Case Report2024
3Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trialRCT · 2016 · 108 citations
4Data from Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).2024
5Abstract B056: The unconfounded effect of bevacizumab on advanced ovarian clear cell carcinoma: a systematic review, traditional meta-analysis, and network meta-analysis2024 · 1 citations